Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 11/20 | 0.61 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.53 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tixanox SCHEMBL31472752 | 1.00 | TTR (0.61) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11859214 | 0.93 | TTR (0.60) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11865408 | 0.92 | TTR (0.59) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11872913 | 0.92 | TTR (0.59) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11858573 | 0.92 | TTR (0.59) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11872123 | 0.92 | TTR (0.59) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11768728 | 0.86 | TTR (0.58) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11767158 | 0.86 | TTR (0.51) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11771233 | 0.85 | TTR (0.50) | TTRAKR1B1KDM4EALDH1A1HPGD | |
| SCHEMBL11768196 | 0.85 | TTR (0.50) | TTRAKR1B1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | ACORDA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | claimed |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | ACORDA THERAPEUTICS, INC. | 2020-05-21 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2011-09-01 | — | — | US | claimed |
| CN-102149282-A | Carbonate prodrugs and methods of using the same | NEUROGESX INC | 2011-08-10 | — | — | CN | claimed |
| EP-2291084-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | Neurogesx, Inc. (US) | 2011-03-09 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2009143297-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | NEUROGESX, INC. (US) | 2009-11-26 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0125654-B1 | PROCESS FOR THE PREPARATION OF ESPECIALLY PHARMACOLOGICALLY ACTIVE COMPOUNDS CONTAINING A SULFOXIDE GROUP | ZAMBON S.p.A. (IT) | 1987-07-29 | — | — | EP | claimed |
| US-4628087-A | Process for the preparation of pharmacologically active compounds containing a sulfoxide group | ZAMBON S.P.A. (IT) | 1986-12-09 | — | — | US | claimed |
| EP-0125654-A2 | Process for the preparation of especially pharmacologically active compounds containing a sulfoxide group | ZAMBON S.p.A. (IT) | 1984-11-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212927-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | TTR 2878/4885AKR1B1 327/4885KDM4E 1604/4885 |
| US-20200157126-A1 | CARBONATE PRODRUGS AND METHODS OF USING THE SAME | CA6, CA7, CA4 | TTR 2878/4885AKR1B1 327/4885KDM4E 1604/4885 |
| US-11136342-B2 | Carbonate prodrugs and methods of using the same | CA6, CA7, CA4 | TTR 2878/4885AKR1B1 327/4885KDM4E 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.